LENZ Therapeutics concludes merger with Graphite Bio

2024-03-22
Pharmaceutical Technology
临床3期临床结果并购孤儿药高管变更
LENZ Therapeutics’s focus will be on advancing presbyopia treatments post-merger. Credit: Prostock-studio / Shutterstock.com.
LENZ Therapeutics has concluded its merger with Graphite Bio, forming a late-stage biopharmaceutical company dedicated to developing treatments for presbyopia.
LENZ Therapeuticsl-stock transaction agreed by tGraphite Bio in November 2023, positions the combined entity under the name LENZ Therapeutics.
The combined company will focus on advancing the lead assets of LENZ Therapeutics for presbyopia treatment.LENZ Therapeutics
With $225m in cash or cash equivalents, the company is poised toLENZ Therapeuticsture presbyopiacialise its lead product candidates, pending Phase III trial outcomes and Food and Drug Administration (FDA) approval.
The financial foundation of the merged company includes $53.5m from a concurrent private investment in public equity financing, contributed by a syndicate of healthcare iFood and Drug Administration (FDA)
See Also:
FDA grants orphan drug status to HI-Bio’s felzartamab for AMR
FDAstol Myers Squibb acquires KarHI-Bioerafelzartamab $14bAMR
LENZ’s existing investors led the syndicate, which also saw participation from new investors.
Bristol Myers Squibbwill lead Karuna Therapeuticsident and CEO, steering it towards its goal of treating a broad demographic of patients with presbyopia.
The product candidates of LENZ are LNZ100 and LNZ101, which are preservative-free, single-use, once-a-day eye drops.
LENZdrops containing aceclidine and a combination of aceclidine plus brimonidine have shown promising results in terms of quick onset and sustained near-vision improvement.
The treatments have also demonstrated effectiveness across a wide age and refractive range of presbyopes without compromising distance vision.presbyopia
Based on the data from the Phase IILNZ100ITY tLNZ101 the company plans to file a new drug application with the FDA by mid-2024.
LENZ’s strategy is toaceclidinelise the most effectivaceclidinefor thbrimonidinenge of presbyopes tested, intending to launch either LNZ100 or LNZ101 in the US through its own commercial organisation.
Schimmelpennink stated: “Following the close of this transaction, we believe we are well-positioned to bring the opportunity of a once-daily pharmacological eye drop intended to improve near vision throughout the full workday closer to the 128 million people in the United States who are impacted by presbyopia.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。